DFM Funding Monitor

Oils4cure: finding an effective drug to alleviate Refractory Epilepsy, one of the most severe symptoms in the pathology of Tuberous Sclerosis Complexbroad

oils4cure · Horizon Europe grant · 2023-12-01–2026-08-31

EC contribution

€1,557,877

Total cost

€2,225,539

Beneficiaries

1

About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →

Objective

OILS4CURE is a Spanish biotech company dedicated to the research, development, production and commercialisation of medicinal products based on full spectrum medicinal cannabis extracts. It is developing a drug to manage refractory epilepsy associated with tuberous sclerosis complex (YCJ-01) and another for Leukodystrophies (YCJ-02), both paediatric rare diseases. This project only deals with the development of our first and most advanced therapy directed at tuberous sclerosis complex (TSC).

Beneficiaries (1)

Organisation	Country	Role	EC contribution	SME
OILS4CURE SL	ES	coordinator	€1,557,877	Yes

Get the DFM funding briefing — free

New EU defence calls, tenders and awards in your inbox.

Countries

Germany France Poland Spain Italy

Sectors

Security equipment Military vehicles Weapons & ammunition Military aircraft Warships & naval Military electronics

Sources

calls tenders awards research

I agree to receive the DFM Analysis briefing and funding alerts by email. I can unsubscribe at any time.

Website

Subscribe free

We store your email only to send the DFM briefing/alerts and to add you to DFM Analysis. Unsubscribe anytime.

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.